A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R1 represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A1 and A2 indicate a double bond (A1=A2), etc.; A1 represents a group represented by the formula C(R2), etc.; A2 represents a group represented by the formula C(R4), etc.; R2 represents hydrogen, optionally substituted alkyl, etc.; R4 represents hydrogen, optionally substituted alkyl, etc.; R6 represents hydrogen, optionally substituted aryl, etc.; and -Y represents, e.g.; a group represented by the formula (A): (A) (wherein ml is 0, 1, 2, or 3; and R7 is absent, or one or two R7's are present and each independently represents optionally substituted alkyl, etc.).]
The invention provides novel substituted heterocyclic compounds represented by Formula I and Formula II, or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of MEK and are useful in the treatment of inflammatory diseases, cancer and other hyperproliferative diseases. The invention further provides a method of treatment for inflammatory diseases, cancer and other hyperproliferative diseases in mammals, especially humans.
2,3,7,8,12,13,17,18-Octakis(.beta.-hydroxyethyl)porphyrin (octaethanolporphyrin) and its liquid crystalline derivatives: synthesis and characterization
作者:Brian A. Gregg、Marye Anne Fox、Allen J. Bard
DOI:10.1021/ja00190a041
日期:1989.4
A synthesis is reported of 2,3,7,8,12,13,17,18-octakis(beta}-hydroxyethyl)porphyrin (octaethanolporphyrin) and a series of its octaalky ether derivatives. A number of the octakis(alkoxyethyl)porphyrins exhibit a discotic liquidcrystalline phase, and all exhibit an isotropic liquid phase. These materials can be prepared as ordered thin films for testing as large-area organic semiconductor devices
A compound represented by the following formula (I), a prodrug thereof, or a pharmaceutically acceptable salt of either. These are compounds having high DPP-IV inhibitory activity and improved in safety, nontoxicity, etc. (I) [In the formula, R
1
represents hydrogen, optionally substituted alkyl, etc.; the solid line and dotted line between A
1
and A
2
indicate a double bond (A
1
=A
2
), etc.; A
1
represents a group represented by the formula C(R
2
), etc.; A
2
represents a group represented by the formula C(R
4
), etc.; R
2
represents hydrogen, optionally substituted alkyl, etc.; R
4
represents hydrogen, optionally substituted alkyl, etc.; R
6
represents hydrogen, optionally substituted aryl, etc.; and —Y represents, e.g.; a group represented by the formula (A): (A) (wherein m1 is 0, 1, 2, or 3; and R
7
is absent, or one or two R
7
's are present and each independently represents optionally substituted alkyl, etc.).]